Quick answer: The software as a medical device market was sized anywhere from $2.1 billion to $36.9 billion for 2025, depending on which analyst you ask, with growth forecasts running from about 7% to 38% a year. That gap in the software as a medical device market is a definitions problem, not a reality problem. The one number you can actually trust is regulatory: the FDA has authorized over 1,600 AI-enabled devices, and the pace is climbing. Quote the range, then size your own slice from the bottom up.
Google the software as a medical device market and you get something that looks like a bug report instead of an answer. One analyst says it was worth $2.1 billion in 2025. Another says $36.9 billion. That is a 17x spread, and if you drop the wrong one into a pitch deck or an investment memo, someone in the room will notice and your credibility takes the hit.
If you are a MedTech founder, a HealthTech investor or a product director at a device company, this guide is for you. We will sort out what really counts as SaMD, why the numbers disagree, and what is going on in the software as a medical device market this year. And if you are still working out how to build the thing, our mobile app development team can show you what a testable, offline-capable build looks like.
What is the software as a medical device market, and what counts as SaMD?
The software as a medical device market is every product that runs software for a medical purpose, like diagnosing, monitoring or guiding treatment, without being part of a hardware device. The IMDRF wrote that definition and the FDA uses it, so it is the one that matters.
Definition: SaMD (Software as a Medical Device). Software intended for one or more medical purposes that does its job without being part of a hardware medical device. Think of an app that reads retinal images for diabetic retinopathy, an algorithm that flags a suspected pneumothorax on a chest X-ray, or software that calculates an insulin dose.
Where people get tripped up is the neighbors. The “medical device software market” is the bigger bucket, and it often includes software baked into hardware, like the firmware inside an infusion pump. That is SiMD, not SaMD. If it helps, think of SaMD as the app and SiMD as the firmware. So when two reports on the software as a medical device market disagree, check which bucket each one is counting.
| Category | What it is | Example | In SaMD estimates? |
|---|---|---|---|
| SaMD | Standalone software with a medical purpose | AI radiology triage tool | Yes |
| SiMD | Software inside a hardware device | Pacemaker or pump firmware | Usually no |
| Production software | Software used to make or maintain devices | Manufacturing quality tools | No |
| Wellness and admin software | No medical purpose | Step counter app | No |
Key takeaway: Before you quote any figure for the software as a medical device market, check whether it counts SaMD only or the wider medical device software market.
What is the software as a medical device market size in 2026?
Honest answer: it depends who you ask. There is no single right SaMD market size. Published estimates for the software as a medical device market in 2025 run from $2.1 billion to $36.92 billion, and most 2026 numbers from the lower and middle of the pack sit around $5 billion to $7 billion. Mordor Intelligence ($5.24 billion), Global Market Insights ($6.5 billion) and 360iResearch ($6.77 billion) all land in that band.
| Publisher | 2025 base | Forecast | CAGR | Period |
|---|---|---|---|---|
| DelveInsight | $2.1B | $8.9B by 2034 | ~17% | 2026 to 2034 |
| Mordor Intelligence | $3.81B | $25.87B by 2031 | 37.62% | 2026 to 2031 |
| Business Research Insights | $3.83B | $101.27B by 2035 | 38.4% | 2025 to 2035 |
| Global Market Insights | $5.8B | $21.1B by 2035 | 13.9% | 2026 to 2035 |
| 360iResearch | $6.33B | $10.47B by 2032 | 7.45% | 2026 to 2032 |
| Roots Analysis | $36.92B | $210.74B by 2035 | 19.0% | 2025 to 2035 |
Why do software as a medical device market estimates differ by 17x?
Most reports on the software as a medical device market sit behind paywalls, so nobody outside can audit the models. It is a bit like comparing benchmarks run on different hardware. Still, four scoping choices usually explain the gap:
- Scope. Some count only regulated, standalone products in the software as a medical device market. Others fold in AI diagnostics platforms, SiMD or the wider medical device software market.
- Revenue definition. Licenses and subscriptions are one thing. Implementation, services and hardware bundles are another.
- Base year and method. Top-down estimates built from adjacent healthcare IT markets run bigger than bottom-up counts of products and prices.
- Segment inclusion. Whether remote monitoring, digital therapeutics and clinical decision support are in or out changes the total fast.
Key takeaway: The SaMD market size is a scope question first and a forecast question second. Cite the range, name the publisher, and lean on the $5 billion to $7 billion 2026 cluster instead of either extreme.
How fast is software as a medical device market growth, and where is the money going?
Forecast SaMD market growth runs from 7.45% a year at the cautious end to 38.4% at the aggressive end, with most reports on the software as a medical device market landing between the mid-teens and the high thirties.
The better signal is where the software as a medical device market concentrates. Screening and early detection held 39.2% of 2025 revenue in the software as a medical device market, driven by autonomous retinal and skin imaging, and chronic-condition management is forecast to grow fastest. North America is the largest regional market, led by diagnostic and screening software.
If you want a reality check on the software as a medical device market, skip the dollar forecasts and count units. The FDA authorized 335 AI-enabled devices in 2025, up 43% from 235 in 2024, and the FDA list passed 1,600 authorizations by September 2026. Dollar forecasts are opinions. Authorizations are public records, a bit like commit history versus a roadmap slide.
Key takeaway: Treat authorizations as the hardest data in the software as a medical device market, and treat revenue forecasts as directional.
What are the software as a medical device market trends 2026?
Five things define the software as a medical device market trends 2026: AI is the default, change plans let models keep learning, the US quality rules got rewritten, Europe moved a deadline, and investors got pickier about where the money goes.
AI is the default, not the differentiator
The FDA authorized 181 AI-enabled devices in the first half of 2026, against 173 in the same stretch of 2025. Radiology makes up 76% of authorizations, and 96% went through the 510(k) pathway. That makes the route into the software as a medical device market predictable, like a well-documented API. It also means imaging is crowded and “we use AI” will not set you apart.
Change control plans work like CI/CD for models
The FDA finalized its guidance on predetermined change control plans in December 2024. In plain terms, you agree with the FDA up front on which model updates you will ship, how you will test them and what “good” looks like, so a retrained model does not need a fresh submission every time. For any learning product in the software as a medical device market, that changes your roadmap and your regulatory budget.
The US quality rule got a spec migration
On February 2, 2026, the FDA’s Quality Management System Regulation took effect. It replaced the old Quality System Regulation and pulled in ISO 13485:2016 by reference. Every maker in the software as a medical device market that sells in the US has to align. If your quality system still uses the old terminology, fix it now, because inspections follow the new process.
Europe moved the AI Act date, not the MDR
High-risk AI obligations for AI in regulated products, including medical devices, moved from August 2027 to August 2028. The Digital Omnibus entered into force on 27 July 2026, and it does not touch the Medical Device Regulation. Devices stay in scope of the software as a medical device market rules in Europe. They just get more runway, and you will still need to satisfy both the AI Act and the MDR.
Money in the software as a medical device market is getting picky
US digital health startups raised $3.7 billion across 114 deals in Q3 2026, bringing the year to $11.1 billion. In the first half, 20 rounds of $100 million or more took 45% of all dollars. Money is flowing into the software as a medical device market, but to a small group of companies with clear deployable value.
Key takeaway: The 2026 story for the software as a medical device market is not growth alone. It is a market where the rules are clearer, the competition is heavier and the money is pickier.
What is driving growth in the software as a medical device market?
Five forces are driving the software as a medical device market, and they feed each other. First, a workable path to market: with 96% of AI authorizations using 510(k), founders can plan around precedent instead of guessing. Second, models that clear clinical bars, especially in screening and imaging, where triaging big populations quickly is exactly what buyers pay for. Third, update rules that do not punish iteration. Fourth, capital for the best teams. Fifth, phones and wearables that carry regulated software outside the clinic.
Key takeaway: Growth in the software as a medical device market follows regulatory clarity and clinical proof, not hype cycles.
What challenges do founders face in the software as a medical device market?
Building the model is the easy part. The hard part is turning a cleared product into revenue, because evidence, integration, reimbursement and procurement all move slower than your sprint board suggests. A large software as a medical device market does not mean your product automatically gets a slice of it.
| Challenge | Why it bites | How to reduce it |
|---|---|---|
| Evidence and regulatory timelines | Clinical validation and QMS setup often take longer than coding | Fix intended use early and run pre-submission meetings |
| Crowded predicates | Imaging is saturated, so “substantially equivalent” is not a moat | Pick a narrow clinical wedge with measurable outcomes |
| Buyer budgets and reimbursement | Hospitals need a payer or a savings story, not just accuracy | Model cost savings per site before you pitch |
| Hospital IT integration | EHR, PACS and SSO work often decides the deal | Design APIs and workflow fit from sprint one |
| Concentrated funding | A few mega-rounds take most dollars | Show pilot revenue and deployment proof |
If you are an engineer, the integration row will feel painfully familiar: it is the legacy-system problem with patient data attached. Many teams in the software as a medical device market treat hospital integration as plumbing, then find out that connecting to hospital systems, identity providers and third-party tools is the longest part of a pilot. Our industry software solutions overview shows how integration-heavy products get scoped.
Key takeaway: In the software as a medical device market, clearance opens the door. Integration, evidence and a buyer’s budget decide whether anyone walks through.
Not Sure Your SaMD Idea Is Worth Building Yet?
EnactOn tests whether a product is worth building for the software as a medical device market before building it, then scopes the software layers with human-reviewed, AI-assisted engineering, so your first release targets a real buyer and a real workflow.
How do you size your slice of the software as a medical device market instead of trusting a TAM?
Start with one intended use and count real buyers, volumes and prices. A bottom-up model of your slice of the software as a medical device market is smaller than a headline TAM, but investors and clinical buyers trust it far more. Here is the six-step version:
- Define the intended use. One clinical claim, one population, one setting.
- Count the buying unit. Imaging centers, clinics, clinicians or patients.
- Estimate volume per unit. Scans per year, visits per month or active patients.
- Set a realistic price. Per study, per seat or per patient per month.
- Apply honest penetration. Early adoption is usually a small share of the total.
- Pressure-test against the range. If your answer exceeds the lowest published total for the software as a medical device market, rethink your assumptions.
As an illustration only, imagine 500 imaging centers, each running 20,000 relevant studies a year at $2 per study. That is a $20 million ceiling at full adoption, and $2 million if you win 10% of centers. It is a modest slice of the software as a medical device market, and it is a number you can defend.
Key takeaway: A small, defensible slice of the software as a medical device market beats a large, unexplained one every time.
So, What’s The Conclusion?
The software as a medical device market is real, growing and noisy. Published sizes span a 17x range because analysts define SaMD differently, while the most reliable evidence, FDA authorizations, shows steady and accelerating adoption. The winners in the software as a medical device market in 2026 will be teams that pair a narrow clinical claim with proof and integration that actually works.
Your next step is simple: write down your intended use, count your buyers and build the bottom-up model before you quote any headline figure for the software as a medical device market. Then check your plan against the 2026 changes, namely PCCPs, the new QMSR and the August 2028 EU AI Act date.
EnactOn builds software products with a market-first approach: we test whether a product is worth building before we build it, use AI-assisted engineering with human review, and keep delivery in-house. We work alongside your regulatory and quality advisers rather than replacing them, and we can scope the mobile, web and integration layers of a SaMD product. If your plan for the software as a medical device market needs a sharper product scope, we are glad to look at it.
FAQs
How big is the software as a medical device market?
Depends on who you ask. Published estimates for the software as a medical device market in 2025 range from $2.1 billion to $36.92 billion, a gap of roughly 17x. Most lower and mid-range reports put 2026 at about $5 billion to $7 billion. The spread comes from how each analyst defines SaMD and what revenue they count, so always cite the publisher and the scope when you quote the SaMD market size.
What is the expected SaMD market growth rate through 2035?
Forecast growth in the software as a medical device market ranges from about 7.45% a year to 38.4%, with many reports in the mid-teens to high thirties. A lower starting base tends to produce a higher percentage, so compare dollar increases as well as CAGRs.
Why do reports on the software as a medical device market disagree so much?
Reports on the software as a medical device market differ on scope, revenue definition, base year and method. Some count only regulated standalone software, while others include AI diagnostics platforms, services or software embedded in devices. Treat each number as an informed estimate.
How is the medical device software market different from the software as a medical device market?
The medical device software market is the broader label. It often includes SiMD, which is software inside hardware like pumps and implants, along with other device-related software. The software as a medical device market covers only standalone software with a medical purpose, so SaMD figures are normally smaller.
What is driving the growth of the software as a medical device market?
Five drivers shape the software as a medical device market: a workable FDA path where 96% of AI authorizations use 510(k), strong AI performance in screening and imaging, flexible update rules through PCCPs, venture capital for the best teams, and consumer devices that distribute regulated software.
Which parts of the software as a medical device market are growing fastest?
Within the software as a medical device market, screening and early detection is the largest application today, and chronic-condition management is forecast to grow fastest.
How long does it take to bring a product into the software as a medical device market?
It depends on risk class, pathway and how much clinical evidence you need, so be wary of anyone promising a fixed number. In practice, evidence generation and quality system setup usually take longer than writing the software, which surprises many newcomers to the software as a medical device market.
What is the biggest commercial challenge for startups in the software as a medical device market?
Getting from clearance to paid deployments in the software as a medical device market. Hospital integration, buyer budgets, reimbursement and procurement cycles are slower than software teams expect.
How does the EU AI Act affect founders in the software as a medical device market in 2026?
High-risk AI obligations for AI in regulated products, including medical devices that need a notified body, now apply from August 2, 2028. The MDR requirements are unchanged, so founders in the software as a medical device market must meet both. Start your documentation now rather than waiting for the later date.
How does EnactOn help early-stage SaMD teams?
For teams entering the software as a medical device market, we start with a market-first check on whether the product is worth building, then scope the mobile, web and integration layers with in-house engineers using AI-assisted development and human review. We test on real devices and connect to third-party systems and SSO providers. We work alongside your regulatory consultants and do not provide regulatory submissions ourselves.
